C. Huggins and C. V. Hodges, “Studies on Prostatic Cancer. I. The Effect of Castration on Serum Phosphatases In Metastatic Carcinoma of the Prostate,” Cancer Research, Vol. 1, No. 1941, pp. 293-296.
 F. Sciarra, G. Sorcini, F. Di Silverio and V. Gagliardi, “Plasma Testosterone and Androstenedione after Orchiectomy in Prostatic Adenocarcinoma,” Clinical Endocrinology (Oxford), Vol. 2, No. 2, 1973, pp. 101-109.
 H. J. de Voogt, P. H. Smith, M. Pavone-Macaluso, M. de Pauw and S. Suciu, “Cardiovascular Side Effects of Diethylstilbestrol, Cyproterone Acetate, Medroxyprogesterone Acetate and Estramustine Phosphate Used for the Treatment of Advanced Prostatic Cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 And 30762,” The Journal of Urology, Vol. 135, No. 2, 1986, pp. 303-307.
 G. Tolis, N. Faure, M. Koutsilieris, A. Lemay, S. Klioze, A. Yakabow and A. T. Fazekas, “Suppression of Testicular Steroidogenesis by the GnRH Agonistic Analogue Buserelin (HOE-766) in Patients with Prostatic Cancer: Studies in Relation to Dose and Route of Administration,” Journal of Steroid Biochemistry, Vol. 19, No. 1C, 1983, pp. 995-998.
 G. Mathe, A. V. Schally, A. M. Comaru-Schally, R. Y. Mauvernay, M. L. Vovan, D. Machover, J. L. Misset, B. Court, P. Bouchard, J. Duchier and et al., “Phase II Trial with D-Trp-6-LH-RH in Prostatic Carcinoma: Comparison with Other Hormonal Agents,” The Prostate, Vol. 9, No. 4, 1986, pp. 327-342.
 H. J. de Voogt, U. Studer, F. H. Schroder, J. G. Klijn, M. de Pauw and R. Sylvester, “Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-term (two weeks) or Long-term (continuous) Cyproterone Acetate is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer. Final Analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group,” European Urology, Vol. 3
 H. Parmar, R. H. Phillips, S. L. Lightman, L. Edwards, L. Allen and A. V. Schally, “Randomised Controlled Study of Orchidectomy vs Long-acting D-Trp-6-LHRH Microcapsules in Advanced Prostatic Carcinoma,” Lancet, Vol. 2, No. 8466, 1985, pp. 1201-1205.
 H. Matzkin, I. Kaver, O. Lewyshon, D. Ayalon and Z. Braf, “The Role of Increased Prolactin Levels under Gnrh Analogue Treatment in Advanced Prostatic Carcinoma,” Cancer, Vol. 61, No. 11, 1988, pp. 2187-2191.
 A. B. Grotas and H. M. Nagler, “Presentation of a Functional Pituitary Adenoma as A Significant Decrease in Prostate-Specific Antigen Level in a Patient Followed for Prostate Cancer,” The Canadian Journal of Urology, Vol. 13, No. 6, 2006, pp. 3346-3347.
 F. G. Robertson, J. Harris, M. J. Naylor, S. R. Oakes, J. Kindblom, K. Dillner, H. Wennbo, J. Tornell, P. A. Kelly, J. Green and C. J. Ormandy, “Prostate Development and Carcinogenesis in Prolactin Receptor Knockout Mice,” Endocrinology, Vol. 144, No. 7, 2003, pp. 3196-3205.
 A. Peyre, J. P. Ravault and P. Laporte, “Potentiation Effect Of Endogenous Prolactin on Male Sex Effectors Treated with Testosterone,” Comptes rendus des séances de la Société de biologie et de ses filiales, Vol. 162, No. 8, 1968, pp. 1592-1595.
 F. Labrie, A. Belanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J. Gomez and B. Candas, “Gonadotropin-releasing Hormone Agonists in the Treatment of Prostate Cancer,” Endocrine Reviews, Vol. 26, No. 3, 2005, pp. 361-379.
 I. M. Spitz, B. Chertin, A. Fridmans, A. Farkas, A. Belanger, H. Hartman and F. Labrie, “Partial Androgen Suppression Consequent to Increased Secretion of Adrenal Androgens in a Patient with Prostate Cancer Treated with Long-acting GnRH Agonists,” Prostate Cancer and Prostatic Diseases, Vol. 12, No. 1, 2009, pp. 100-103.
 E. Ciccarelli, M. Giusti, C. Miola, F. Potenzoni, D. Sghedoni, F. Camanni and G. Giordano, “Effectiveness and Tolerability of Long Term Treatment with Cabergoline, a New Long-lasting Ergoline Derivative, in Hyperprolactinemic Patients,” The Journal of Clinical Endocrinology and Metabolism, Vol. 69, No. 4, 1989, pp. 725-728.
 E. Delgrange, T. Daems, J. Verhelst, R. Abs and D. Maiter, “Characterization of Resistance to the Prolactin-lowering Effects of Cabergoline in Macroprolactinomas: A Study in 122 Patients,” The European Journal of Endocrinology, Vol. 160, No. 5, 2009, pp. 747-752.
 F. A. Laszlo, C. Varga, A. Papp, I. Pavo and F. Fahrenholz, “Difference between Male and Female Rats in Vasopressor Response to Arginine Vasopressin,” Acta Physiologica Hungarica, Vol. 81, No. 2, 1993, pp. 137-145.
 F. F. Casanueva, M. E. Molitch, J. A. Schlechte, R. Abs, V. Bonert, M. D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L. G. Sobrinho, J. A. Wass and A. Giustina, “Guidelines of the Pituitary Society for the Diagnosis and Management of Prolactinomas,” Clinical Endocrinology (Oxford), Vol. 65, No. 2, 2006, pp. 265-273.